Generic Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics

Wednesday, June 7, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 7, 2017 /PRNewswire/ --

On Tuesday, June 06, 2017, US markets saw broad

based losses with six out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,275.06, down 0.33%; the Dow Jones Industrial Average edged
0.23% lower, to finish at 21,136.23; and the S&P 500 closed at 2,429.33, down 0.28%. This Wednesday morning, looks at the performance of these four Drugs - Generic stocks: Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Lannett Co. Inc. (NYSE: LCI), Evoke Pharma Inc. (NASDAQ: EVOK), and Galectin Therapeutics Inc. (NASDAQ: GALT). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:

Catalyst Pharma 

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock finished Tuesday's session 2.94% lower at $2.31 with a total trading volume of 382,535 shares. The Company's shares have surged 36.69% in the past month, 106.25% over the previous three months, and 120.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 21.67% and 73.14%, respectively. Furthermore, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have a Relative Strength Index (RSI) of 65.77. Visit us today and download your complete report on CPRX for free at:


Shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. ended at $19.65, down 0.25% from the last trading session. The stock recorded a trading volume of 428,488 shares. The Company's shares are trading 13.26% below their 50-day moving average. Moreover, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 36.78. The complimentary research report on LCI can be accessed at:

Evoke Pharma 

Solana Beach, California headquartered Evoke Pharma Inc.'s stock ended yesterday's session 0.78% higher at $2.57 with a total trading volume of 67,077 shares. The Company's shares have advanced 27.23% on an YTD basis. The stock is trading 9.10% above its 200-day moving average. Additionally, shares of Evoke Pharma, which focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, have an RSI of 43.12. Register for free on and download the research report on EVOK at:

Galectin Therapeutics 

On Tuesday, shares in Norcross, Georgia-based Galectin Therapeutics Inc. recorded a trading volume of 312,987 shares. The stock finished 1.74% higher at $2.34. The Company's shares have advanced 37.65% in the previous three months and 138.82% since the start of this year. The stock is trading above its 200-day moving average by 42.50%. Furthermore, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have an RSI of 44.13. Get free access to your research report on GALT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store